Showing 1 - 3 results of 3 for search '"thalidomide"', query time: 0.06s Refine Results
  1. 1
    Association of Chromosome 17 Aneuploidy, <i>TP53</i> Deletion, Expression and Its rs1042522 Variant with Multiple Myeloma Risk and Response to Thalidomide/Bortezomib Treatment

    Association of Chromosome 17 Aneuploidy, <i>TP53</i> Deletion, Expression and Its rs1042522 Variant with Multiple Myeloma Risk and Response to Thalidomide/Bortezomib Treatment by Sylwia Popek-Marciniec, Wojciech Styk, Magdalena Wojcierowska-Litwin, Sylwia Chocholska, Aneta Szudy-Szczyrek, Marzena Samardakiewicz, Grazyna Swiderska-Kolacz, Joanna Czerwik-Marcinkowska, Szymon Zmorzynski

    Published 2023-09-01
    Get full text
    Article
  2. 2
    Circulating Serum MiRNA-8074 as a Novel Prognostic Biomarker for Multiple Myeloma

    Circulating Serum MiRNA-8074 as a Novel Prognostic Biomarker for Multiple Myeloma by Aneta Szudy-Szczyrek, Radosław Mlak, Michał Mielnik, Marcin Mazurek, Sylwia Chocholska, Martyna Podgajna, Michał Szczyrek, Iwona Homa-Mlak, Teresa Małecka-Massalska, Marek Hus

    Published 2022-02-01
    “…In total, 105 newly diagnosed MM patients treated with thalidomide (n = 27), bortezomib (n = 41) and bortezomib with thalidomide (n = 37) were studied. …”
    Get full text
    Article
  3. 3
    Efficacy of ixazomib-lenalidomide-dexamethasone in high-molecular-risk relapsed/refractory multiple myeloma – case series and literature review

    Efficacy of ixazomib-lenalidomide-dexamethasone in high-molecular-risk relapsed/refractory multiple myeloma – case series and literature review by Aneta Szudy-Szczyrek, Sylwia Chocholska, Oliwia Bachanek-Mitura, Olga Czabak, Radosław Mlak, Michał Szczyrek, Justyna Muzyka-Kasietczuk, Marek Hus

    Published 2021-06-01
    “…Previous chemotherapy regimens included thalidomide and bortezomib. Median duration of exposure to ixazomib was 12 months. …”
    Get full text
    Article

Search Tools: